This inventor holds 3 USPTO granted patents. Top assignee: Dana-Farber-Cancer Institute Inc.. Active years: 1993-1999.
Company Filing History:
Years Active: 1993-1999
Title: Mark E Ewen: Innovator in Tumor Suppression and Gene Therapy
Introduction
Mark E Ewen is a prominent inventor based in Brookline, MA (US). He has made significant contributions to the field of cancer research, particularly in the area of tumor suppression and gene therapy. With a total of 3 patents, Ewen's work has the potential to impact the diagnosis and treatment of various cancers.
Latest Patents
Ewen's latest patents include groundbreaking inventions related to the p107 tumor suppressor. One of his patents describes a cDNA that encodes p107, which can be used in cells to contain recombinant p107-encoding DNA. This innovation is crucial for understanding tumorigenicity in subjects. Another patent outlines a method for diagnosing tumorigenicity by detecting the presence or absence of wild-type p107-encoding genes in tissue samples. Additionally, he has developed a nucleic acid probe that is complementary to a portion of a human mutant p107 gene. His work also includes a nucleic acid encoding transcription factor p300, which is essential for adenovirus transformation of mammalian cells.
Career Highlights
Mark E Ewen is affiliated with the Dana-Farber Cancer Institute Inc., where he continues to advance his research. His career is marked by a commitment to understanding the genetic underpinnings of cancer and developing innovative diagnostic methods.
Collaborations
Ewen has collaborated with notable colleagues in the field, including David M Livingston and Richard Eckner. These partnerships have further enriched his research and contributed to the advancement of cancer therapies.
Conclusion
Mark E Ewen's contributions to cancer research through his patents and collaborations highlight his role as an innovator in the field. His work continues to pave the way for advancements in tumor suppression and gene therapy.